Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Teva
Deloitte
Express Scripts
Accenture
Johnson and Johnson
QuintilesIMS
Fish and Richardson

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,980,327

« Back to Dashboard

Which drugs does patent 8,980,327 protect, and when does it expire?

Patent 8,980,327 protects FOSRENOL and is included in one NDA.

This patent has ten patent family members in nine countries.
Summary for Patent: 8,980,327
Title:Capsule and powder formulations containing lanthanum compounds
Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.
Inventor(s): Pierce; David (Hertfordshire, GB), Ferdinando; Josephine Christine (Tadley, GB), Davies; Peter Neil (Basingstoke, GB)
Assignee: Shire LLC (Florence, KY)
Application Number:14/507,439
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,980,327

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,980,327

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,023,397 Capsule and powder formulations containing lanthanum compounds ➤ Sign Up
8,263,119 Capsule formulations containing lanthanum compounds ➤ Sign Up
8,697,132 Capsule and powder formulations containing lanthanum compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
Citi
Dow
McKesson
Cipla
Chinese Patent Office
US Department of Justice
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.